TG Therapeutics Inc (TGTX)
16.23
-0.19
(-1.16%)
USD |
NASDAQ |
May 03, 12:00
TG Therapeutics Cash from Investing (Quarterly): -44.76M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -44.76M |
| September 30, 2023 | -30.23M |
| June 30, 2023 | 30.50M |
| March 31, 2023 | -6.168M |
| December 31, 2022 | 16.27M |
| September 30, 2022 | -2.99M |
| June 30, 2022 | 10.38M |
| March 31, 2022 | -43.67M |
| December 31, 2021 | 3.288M |
| September 30, 2021 | -0.631M |
| June 30, 2021 | -2.475M |
| March 31, 2021 | -0.514M |
| December 31, 2020 | -52.08M |
| September 30, 2020 | 14.91M |
| June 30, 2020 | 11.20M |
| March 31, 2020 | 1.45M |
| December 31, 2019 | 0.004M |
| September 30, 2019 | -0.044M |
| June 30, 2019 | 0.457M |
| March 31, 2019 | -1.135M |
| December 31, 2018 | 0.238M |
| September 30, 2018 | -6.435M |
| June 30, 2018 | 5.585M |
| March 31, 2018 | 1.792M |
| December 31, 2017 | -28.01M |
| Date | Value |
|---|---|
| September 30, 2017 | 8.80M |
| June 30, 2017 | 4.998M |
| March 31, 2017 | 6.00M |
| December 31, 2016 | 11.48M |
| September 30, 2016 | 15.58M |
| June 30, 2016 | 1.414M |
| March 31, 2016 | -1.924M |
| December 31, 2015 | 2.478M |
| September 30, 2015 | 0.0766M |
| June 30, 2015 | -31.08M |
| March 31, 2015 | 3.843M |
| December 31, 2014 | -9.133M |
| September 30, 2014 | -0.0013M |
| June 30, 2014 | -9.218M |
| March 31, 2014 | -0.0032M |
| December 31, 2013 | -4.922M |
| September 30, 2013 | -0.0016M |
| June 30, 2013 | -0.0017M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.0014M |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.0104M |
| September 30, 2011 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-52.08M
Minimum
Dec 2020
30.50M
Maximum
Jun 2023
-5.005M
Average
-0.044M
Median
Sep 2019
Cash from Investing (Quarterly) Benchmarks
| Amicus Therapeutics Inc | -23.96M |
| Geron Corp | 47.57M |
| Editas Medicine Inc | 62.84M |
| G1 Therapeutics Inc | -7.647M |
| Mersana Therapeutics Inc | 20.15M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.21M |
| Cash from Financing (Quarterly) | -0.001M |
| Free Cash Flow | -31.41M |
| Free Cash Flow Per Share (Quarterly) | -0.0846 |
| Free Cash Flow to Equity (Quarterly) | -113.33M |
| Free Cash Flow Yield | -1.30% |